Galectin Therapeutics Inc.
Symbol: GALT (NASDAQ)
4.30
▲ (1.42%) 0.060
Company Description:
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Key Stats
- Today's Open: $4.278
- Today's High: $4.295
- Today's Low: $4.278
- Today's Volume: 110
- Yesterday Close: $4.235
- Yesterday High: $4.4345
- Yesterday Low: $4.08
- Yesterday Volume: 270.72K
- Last Min Volume: 100
- Last Min High: $4.295
- Last Min Low: $4.295
- Last Min VWAP: $4.295
Company Profile
- Name: Galectin Therapeutics Inc.
- Website: https://www.galectintherapeutics.com
- Listed Date: 2002-09-04
- Location: NORCROSS, GA
- Market Status: Active
- CIK Number: 0001133416
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $271.30M
- Round Lot: 100
- Outstanding Shares: 64.06M
- Asset Type: CS
RECENT FILINGS FOR GALT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-15 | 4 | View |
| 2025-09-15 | 4 | View |
| 2025-09-12 | 144 | View |
| 2025-09-12 | 144 | View |
| 2025-09-08 | 8-K | View |
| 2025-08-14 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-07-22 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-09 | 8-K | View |
| 2025-06-16 | 8-K | View |
| 2025-06-11 | 4 | View |
| 2025-06-11 | 5 | View |
| 2025-05-15 | 8-K | View |
| 2025-05-15 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-03-31 | 8-K | View |
| 2025-03-31 | 10-K | View |
| 2025-03-05 | 4 | View |
| 2025-03-05 | 8-K | View |
Latest News on GALT